Advances in the Management of Central Nervous System Metastases in Non-Small Cell Lung Cancer

Simple Summary Central nervous system (CNS) metastases are common and challenging to manage among patients with non-small cell lung cancer (NSCLC). Here we provide an overview on lung cancer CNS metastases, including our evolving understanding of the genetic landscape, treatment updates, and future directions. Central nervous system (CNS) metastases are common among patients with non-small cell lung cancer (NSCLC). While the presence of brain metastases has historically portended poor prognosis, recent advances in local and systemic therapies have greatly improved outcomes for NSCLC patients with CNS involvement. Stereotactic radiology surgery (SRS) has emerged as an effective radiotherapy technique with fewer toxicities compared to whole brain radiotherapy (WBRT). Furthermore, multi-generation tyrosine kinase inhibitors (TKIs) with CNS overall response rates (ORR) of up to 70-80% are now an accepted first-line approach for a subset of advanced NSCLC patients with targetable molecular alterations. In addition, while the CNS was once considered an immunologic sanctuary site, growing evidence shows that immune checkpoint inhibitors (ICIs) can induce durable responses in brain metastases as well. Ongoing efforts to optimize CNS metastases management are necessary to refine multimodal treatment approaches and develop new therapeutics with better CNS penetrance.

Automated summary

Central nervous system (CNS) metastases are common among patients with non-small cell lung cancer (NSCLC). Recent advances in local and systemic therapies have greatly improved outcomes for NSCLC patients with CNS involvement. Ongoing efforts are necessary to optimize CNS metastases management and develop new therapeutics.